In Silico Stability Analysis and Phosphorylation Induced Structural Simulation of Alpha-synuclein in Parkinson’s disease

Authors

  • Pritam Kumar Panda School of Biotechnology and Bioinformatics, D. Y. Patil University, Navi Mumbai, India
  • Sneha Patil School of Biotechnology and Bioinformatics, D. Y. Patil University, Navi Mumbai, India
  • Priyam Patel School of Biotechnology and Bioinformatics, D. Y. Patil University, Navi Mumbai, India

DOI:

https://doi.org/10.37591/(rrjobi).v2i1.373

Abstract

Alpha-synuclein (α-syn) is the major component of pathologic inclusions that characterizes neurodegenerative disorders such as Parkinson’s disease (PD), dementia with Lewy body disease, and multiple system atrophy. Mutations and phosphorylation of α-syn causes familial PD. Phosphorylation of α-syn at TYR125 and SER129 plays an important role in PD and enhances its partial digestion by calpains leading to its aggregation; however, the exact mechanism is unknown. The present study uses in silico based approach to unravel this obscure mechanism. Phosphorylation of residues Ser-87, Tyr-125 and Ser-129 was performed for both wild-type and reported mutations, viz., A53T, A30P, and E46K. The authors modeled and validated these mutants and also analyzed the energy variation (force fields) to correlate their significance in stability of proteins. Noteworthy implications include changes in stability of proteins after being simulated using NAMD (VMD). The degradation of the protein by proteolytic enzyme calpain leads to the formation of β-sheet-like oligomer which further gives rise to Lewy bodies which is the hallmark of PD.

 

Keywords: α-synuclein, phosphorylation, amyloid, mutations, simulation, NAMD (VMD), protein-protein docking

 

Downloads

Published

2019-03-11

Issue

Vol. 2 No. 1 (2015)

Section

Research Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.